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Obesity is a multifactorial condition resulting from improper balances of hormones and gene expression induced by the diet.
Obesity also has a strong inﬂammatory component that can be driven by diet-induced increases in arachidonic acid. The purpose
of this paper is to discuss the molecular targets that can be addressed by anti-inﬂammatory nutrition. These molecular targets
range from reduction of proinﬂammatory eicosanoids to the modulation of features of the innate immune system, such as toll-
like receptors and gene transcription factors. From knowledge of the impact of these dietary nutrients on these various molecular
targets, it becomes possible to develop a general outline of an anti-inﬂammatory diet that can oﬀer a unique synergism with more
traditional pharmacological approaches in treating obesity and its associated comorbidities.
1.Introduction
It is becoming more evident that inﬂammation plays an
important role in the metabolic consequences of obesity, as
well as other chronic degenerative conditions [1–3]. How-
ever,theunderstandingofthemolecularmechanismsbehind
the control of the inﬂammatory process at the genetic level is
only beginning to be understood. Pharmacology allows one
to determine which parts of the inﬂammatory process are
important in treatment of obesity. However, understanding
how natural components of the diet can also aﬀect the same
molecular targets as pharmacological interventions could
provide attractive and cost-eﬀective alternatives to more
traditional pharmacologic interventions.
The purpose of this paper is to begin to establish linkages
betweendiet,hormones,andgeneticfactorsaﬀectinginﬂam-
mation, and while proposing alternative approaches for the
treatment of obesity and its metabolic consequences driven
by chronic low-level inﬂammation.
2.ANewPerspectiveonObesity
The percentage of overweight and obese individuals appears
tohavestabilizedintheUnitedStatesatabout2/3oftheadult
population [4]. Furthermore despite being exposed to the
same obesogenic environment, about 30% of adults appear
to be resistant to the development of excess body weight.
Thiswouldsuggestthatastronggeneticcomponentmightbe
involved with the current obesity epidemic. This would also
indicate that there may be genetic factors that when activated
by the diet could be responsible for the rapid change.
Thereforeitwouldbehighlydesirabletodeterminehowdiet-
induced chronic low-level inﬂammation could impact the
expression of genes that can aﬀect fat accumulation and the
metabolic consequences after its accumulation.
3. Overview of Inﬂammation
We are in a constant struggle with microbes. The inﬂam-
matory responses that developed over millions of years of
evolution allow us to coexist with them and to maintain a
state of wellness. Most think of inﬂammation in terms of
the pain associated with cellular destruction that comes as a
result of the inﬂammatory response. This is why the ancient
Greeks described inﬂammation as the internal ﬁre. The
ancient Roman physician Celsus described inﬂammation as
pain,swelling,redness,andheat.Thosearetermsstillusedby2 Journal of Obesity
manyphysicianstodescribetheinﬂammatoryprocess.Today
we know the inﬂammatory process is a complex interaction
of both the pro- and anti-inﬂammatory phases [5, 6]. The
pro-inﬂammatory phase induces pain, swelling, redness and
heat, which are indicators that cellular destruction is taking
place. Yet there are equally important anti-inﬂammatory
mechanisms of the inﬂammation process that are necessary
for cellular repair and regeneration. Only when these two
phases are continually balanced, and progenitor endothelial
cells can eﬀectively repair the microtissue injury that results
from inﬂammatory events, that molecular wellness is re-
established. However, if the pro-inﬂammatory phase contin-
ues at a low, but chronic level that is below the perception
of pain, its presence can become a driver of many chronic
diseases.
T h e r ea r es e v e r a le v e n t st h a tc a nt u r no ni n ﬂ a m m a t o r y
responses. The most obvious is microbial invasion. Injuries
and burns (both chemical and radiation) can also induce
the most basic components of the inﬂammatory response.
However, we are now beginning to understand how diet can
also activate the same inﬂammatory responses induced by
microbes.
All of these diﬀerent factors can turn on inﬂammation
through the innate immune response. The primary cellular
components of the innate immune system include toll-
like receptors, cytokine receptors, and various transcription
factors that work together to activate the expression of
inﬂammatory genes that amplify the pro-inﬂammatory
attack phase of inﬂammation.
4. Types of Inﬂammation
Therearetwodistincttypesofinﬂammation.Theﬁrsttypeis
inﬂammation resulting in acute pain. This can be considered
classical inﬂammation. A second type of inﬂammation can
be described as chronic low-level inﬂammation that is
below the threshold of pain. This can be termed “silent
inﬂammation” [7–9]. Since there is no pain associated with
this type of inﬂammation, nothing is done to stop it,
and thus it can linger for years, if not decades, causing
continual organ damage. As long as appropriate reparative
mechanisms and the regenerative/compensatory potential
of organs and tissues are maintained, the development
of chronic degenerative conditions could be prevented or
delayed. However, eventually, exhaustion of the repara-
tive/regenerationpotential willoccur,withsubsequentorgan
damage, loss of function and the onset of overt chronic
disease although the initiating pathogenetic events may have
started decades earlier, triggered by the underlying silent
inﬂammation process.
Both types of inﬂammation are primarily driven by
the production of pro-inﬂammatory eicosanoids derived
from arachidonic acid (AA). AA is an omega-6 fatty acid
whose levels are entirely controlled by the diet. Anti-
inﬂammatory drugs interact with molecular targets that are
downstream from AA, primarily by either inhibiting the
enzymes that convert AA into pro-inﬂammatory eicosanoids
or inhibiting the release of AA from phospholipids in the
membrane. Anti-inﬂammatory nutrition works upstream
by reducing the levels of AA. The overall goal (reduc-
tion of pro-inﬂammatory eicosanoids) remains the same,
but the mechanisms to reach that goal are very diﬀer-
ent.
5. InnateImmune System
The linkage of diet and inﬂammation lies within the innate
immune system. The innate immune system is the most
primitive part of our overall immunological response. As
a result, it has been conserved for hundreds of millions of
years of evolution and is sensitive to nutrients [10]. More
importantly, its activation of the inﬂammatory response
is based on primitive pattern recognition. This is why
the diet remains intimately connected to the regulation
of inﬂammation. Certain food components can activate
the inﬂammatory process of the innate immune system,
and others can inhibit it. When advances in molecular
biology ﬁnally began to unravel the control mechanisms
inherent in the innate immune system, a more detailed
understanding of unexpected mechanisms for a variety
of commonly used pharmacological drugs was achieved
[11, 12]. Likewise, these same advances illustrate how
the diet could aﬀect inﬂammation induced by the innate
immune system. Today the understanding of the linkage
of toll-like receptors, signaling pathways, gene transcription
factors, and silent inﬂammation allows nutrition to evolve
to a new level of gene therapy, especially the silencing
of genes involved in the generation of silent inﬂamma-
tion.
6. ClinicalMarkersof SilentInﬂammation
It is very diﬃcult to discuss a concept of silent inﬂammation
if you cannot measure it, especially since there is no pain
associatedwithit.Itisonlyrecentlythatnewclinicalmarkers
of silent inﬂammation have emerged. The ﬁrst of these
clinical markers is high-sensitivity C-reactive protein (hs-
CRP). It is not a very selective marker since simple infections
can raise it [13–15]. A much more selective marker of silent
inﬂammation is the ratio of two key fatty acids in the blood.
The ﬁrst is the omega-6 fatty acid arachidonic acid (AA),
which is the precursor to pro-inﬂammatory eicosanoids. The
other fatty acid is the omega-3 fatty acid eicosapentaenoic
acid (EPA), which generates anti-inﬂammatory eicosanoids.
The higher the AA/EPA ratio in the blood, the greater the
level of the silent inﬂammation that is likely to be found in
various organs [7–9].
7. DietaryOriginof SilentInﬂammation:
The Perfect Nutritional Storm
There has not been one dietary change alone in past 30 years
thathasincreasedthelevelsofsilentinﬂammation.However,
therehasbeenaconvergenceofthreedistinctdietarychanges
that can be termed as “The Perfect Nutritional Storm” [9].
These dietary factors includeJournal of Obesity 3
(i) increased consumption of reﬁned carbohydrates,
(ii) increased consumption of reﬁned vegetable oils rich
in omega-6 fatty acids,
(iii) decreased consumption of long-chain omega-3 fatty
acids.
The ﬁrst of these dietary changes is the increased
consumption of reﬁned carbohydrates that has signiﬁcantly
increased the glycemic load of the diet. The glycemic load of
a meal is deﬁned as the amount of a particular carbohydrate
that is consumed at a meal multiplied by its glycemic index
[16, 17]. Today high glycemic-index carbohydrates are not
only the major components in virtually all processed foods,
but also in potato, rice, and white bread products. As the
cost of production of reﬁned carbohydrates has dramatically
decreased in the past 25 years, the availability of products
made from these ingredients has dramatically increased [18].
Increased consumption of reﬁned food products generates
meals with a high glycemic load. This results in the increased
secretion of the insulin necessary to lower the resulting
postprandial rise in blood glucose [17].
However, increased insulin production alone is not
suﬃcient to explain the rapid increase in silent inﬂamma-
tion. This requires the presence of another recent dietary
component: the increased consumption of reﬁned vegetable
oils rich in omega-6 fatty acids. The primary fatty acid in
the most common vegetable oils is the omega-6 fatty acid
known as linoleic acid. Until the last 50 years linoleic acid
has been a relatively minor component of the human diet.
As an example, traditional cooking fats such as butter, lard,
and olive oil contain less than 10% linoleic acid. Common
vegetable oils such as corn, soy, sunﬂower, and saﬄower
contain 50%–75% linoleic acid. The usage of these vegetable
oils has increased by more than 400% since 1980 [19]. Since
reﬁnedcarbohydratesandvegetableoilsarenowthecheapest
source of calories [18, 20–22], it is not surprising that the
combination of these two dietary trends has increased the
production of AA thus leading to an epidemic increase in
silent inﬂammation.
There is epidemiological evidence that suggests that high
intake of omega-6 fatty acids may have a potential car-
diovascular beneﬁt [23, 24]. However, this epidemiological
hypothesis was tested in a carefully controlled secondary
prevention trial [25, 26]. This study, known as the Lyon
Diet Heart Study, placed patients who already had a previous
heart attack into one of two intervention groups. The ﬁrst
group followed a diet rich in omega-6 fatty acids following
the American Heart Association dietary guidelines. The
other group followed a diet that was low in omega-6 fatty
acids. After 3.5 years the group with the low omega-6
fatty acid intake had 70% fewer fatal and nonfatal heart
attacks and a complete elimination of sudden cardiac death
comparedto the group following the high omega-6 fatty acid
diet.
The impact of a high omega-6 fatty acid diet can be
understood from the metabolic pathway of linoleic acid










Figure 1: Metabolism of Omega-6 Fatty Acids.
The two rate-limiting steps in this metabolic cascade
of linoleic acid to arachidonic acid are the enzymes delta-
6 and delta-5 desaturase. These enzymes insert cis-double
bonds into unique positions in the omega-6 fatty acid
molecule. Normally, these steps are very slow, thus limiting
the production of AA. However, insulin is a strong activator
of each of these enzymes [27–30]. This means that a high
glycemic-loaddietcoupledwithincreasedintakeofvegetable
oils rich in linoleic acid will lead to increased production
of AA and a corresponding increase in silent inﬂamma-
tion.
Finally, there is the role of the omega-3 fatty acid
EPA in this metabolic cascade and its eﬀect on silent
inﬂammation. In high enough concentrations, EPA can
partially inhibit the activity of the delta-5-desaturase enzyme
thus reducing AA formation by acting as a weak feedback
inhibitor as both fatty acids use the same enzyme for their
production. More importantly, an increased EPA content in
themembranephospholipidsdecreasesthereleaseofAAthat
is necessary to make pro-inﬂammatory eicosanoids. In this
regard, increased consumption of EPA dilutes out existing
AA, thus decreasing the production of pro-inﬂammatory
eicosanoids. Finally, EPA is the molecular building block to
powerful anti-inﬂammatory eicosanoids known as resolvins
[31–34].
Unfortunately, the consumption of long-chain omega-3
fatty acids, such as EPA, has dramatically decreased over the
past century [35]. With that decrease in EPA intake coupled
with the increased consumption of reﬁned carbohydrates
and vegetable oils, the dietary stage was set for a dramatic
increase in silent inﬂammation.4 Journal of Obesity
8. How Obesity InducesChronicDisease
Obesity can be deﬁned as accumulation of excess body fat.
However, it is the location of that excess body fat that deter-
mines whether or not obesity leads to acceleration of chronic
diseases. If the extra body fat is constrained to the adipose
tissueandthereisnocompromiseofmetabolicfunction,that
obese individual would be considered metabolically healthy
[36]. Apparently 1/3 of obese Americans fall into this cat-
egory [37]. On the other hand, if increasing amounts of the
excessfatbecomedepositedinotherorgans(muscles,cardiac
tissue, liver, pancreas), this is known as lipotoxicity [38–
40]. With lipotoxicity comes an acceleration of those chronic
diseases (diabetes, heart disease, cancer, etc.) associated with
obesity. The extent of lipotoxicity will be determined by the
health of the fat cells in the adipose tissue.
9. Adipose Tissue as a Staging Area for
Systemic Silent Inﬂammation
The adipose tissue is the only organ in the body that can
safely store triglycerides. As a consequence, it occupies the
central position in controlling silent inﬂammation by acting
as a fat-buﬀering system especially by controlling the blood
levels of AA. Healthy fat cells have the ability to extract
any excess fatty acid (including AA) in the blood and to
safely store it as a triglyceride. In addition, the adipose
tissue can readily induce the formation of new fat cells from
internal stem cells to increase the storage of increasing levels
of circulating fat in blood coming from either ingestion
of dietary fat or metabolism of excess carbohydrates and
protein that have been converted into circulating fat by the
liver [41].
10.FatCellLife Cycle
The deﬁnition of a healthy fat cell is one that can easily
expand to sequester incoming fats, in particular, for long-
termstorage,andalsogovernsthecontrolledreleaseofstored
fat for ATP production in the peripheral tissues. The ability
to sequester circulating fat into the fat cell depends upon the
integrity of insulin signaling that brings adequate levels of
glucoseintothefatcellthatcanbeconvertedtoglycerol.This
necessarystepisrequiredtoconvertincomingfreefattyacids
into triglycerides for long-term storage.
The problem begins to arise when AA levels become
too great in a particular fat cell. As an initial defensive
mechanism, the generation of new fat cells is induced by
metabolites of AA [42, 43]. Although this is associated
with greater adiposity [44], the creation of new healthy
fat cells maintains the capacity of the adipose tissue to
prevent potential lipotoxicity. However, as the AA levels
continue to increase in any particular fat cell, the cell’s
response to insulin signaling becomes compromised due
to internal silent inﬂammation that interrupts the ﬂow of
glucose into the fat cell to provide the necessary glycerol for
fatty acid storage [45]. It appears this is a consequence of the
generation of pro-inﬂammatory eicosanoids (leukotrienes)
t h a ta r ed e r i v e df r o mA A[ 46, 47]. As a result, the fat cell has
am o r ed i ﬃcult time sequestering newly formed AA as well
asotherfattyacidscirculatingintheblood.Atthesametime,
insulin inhibition of the hormone-sensitive lipase in that
particularfatcellbecomescompromisedbecauseofthesame
disruption in the insulin-signaling cascade. As a result, more
free fatty acids are being released into circulation [48, 49].
These are the hallmarks of classical insulin resistance. It
appears that insulin resistance due to increased AA levels
may arise in the fat cell prior to developing in the muscle
cells [50, 51]. As a result, greater amounts of AA remain in
circulation to be taken up by other cells potentially leading
to acceleration of insulin resistance in the muscle cells,
which in turn causes increased hyperinsulinemia. To further
compound the situation, a compromised fat cell is releasing
greater amounts of previously sequestered AA in the fat cells
into the circulation [52].
As the levels of AA further increase in any one particular
fat cell beyond a critical threshold barrier, cell death can take
place [53]. The necrosis of that particular fat cell causes a
migration of macrophages into the adipose tissue [54, 55].
This increase in macrophage accumulation in the adipose
tissue is clearly seen in both animal models of obesity as
well as in humans [56]. These newly recruited macrophages
cause the secretion of additional inﬂammatory mediators,
such as IL-1, IL-6 and TNFα, which increase inﬂammation
within the adipose tissue [57–69]. These newly released
inﬂammatory cytokines can interact with their receptors at
the surface of nearby fat cells to signal a further activation
of NF-κB, the key gene transcription factor that drives
the inﬂammatory responses of the innate immune system.
Support for this hypothesis of AA-driven inﬂammation in
the fat cells comes from the observations that the amount
of macrophage accumulation can be signiﬁcantly reduced
upon supplementation with high-dose ﬁsh oil rich in EPA
to reduce the inﬂammation in the adipose tissue [70–72].
As inﬂammation in the adipose tissue increases,
inﬂammatory cytokines, such as IL-6 derived from the
macrophages attracted to the inﬂamed fat cells, can exit
into the circulatory system to cause an increase in CRP
formation in the liver. Hence the correlation between
obesity and CRP levels [73]. Likewise TNFα generated by
the same macrophages causes further insulin resistance in
the surrounding fat cells, thus decreasing their ability to
sequester newly formed AA as well as causing the release
of even more stored AA into the circulatory system. In
many ways, the staging area for insulin resistance in other
organs (muscles, liver, and eventually the pancreas) can be
considered to start in the adipose tissue. As insulin resistance
spreads to other organs, the end result is lipotoxicity in the
muscle cells (both smooth muscle and cardiac muscle), liver,
and the beta cells in the pancreas.
As long as the adipose tissue is composed of healthy fat
cells, any increased production of dietary-induced AA can be
safely handled by their continued expansion that can rapidly
remove any excess AA from the blood and store it safely in
the fat cells. In the absence of a large percentage of healthy
fatcellsin the adipose tissue, the combination of the growing
lack of ability to sequester AA from the blood coupled withJournal of Obesity 5
theacceleratedreleaseofstoredAAfromthefatmassintothe
circulationissimilartothemetastaticspreadofatumor;only
now it is silent inﬂammation that is spreading. Depositions
of lipid droplets that cause lipotoxicity characterize this
metastasis of silent inﬂammation. If these accumulated lipid
droplets are also enriched in AA, then the development
of inﬂammatory diseases, such as type 2 diabetes, will be
accelerated.
Understanding the role of healthy fat cells may explain
why approximately one-third of obese individuals are actu-
ally quite healthy [37]. These individuals appear to have
higher levels of the adipose-derived hormone adiponectin
[74]. This is conﬁrmed by studies of the overexpression of
adiponectin in diabetic animals [75]. It should be noted
that adiponectin is an adipose-derived hormone that can be
increased by high levels of ﬁsh oil rich in EPA possibly acting
through the PPARγ transcription factor [76–78].
One of the ﬁrst indications that lipotoxicity is taking
place is the appearance of metabolic syndrome. Metabolic
syndrome can be considered to be prediabetes. It is charac-
terized by a combination of clinical markers, such as a high
TG/HDL ratio, increasing abdominal fat, and hyperinsuline-
mia. Recent data indicate that there is a strong correlation
between metabolic syndrome and levels of AA in the adipose
tissue [50].
Left untreated, metabolic syndrome will usually result in
thedevelopmentoftype2diabeteswithin8–10years.During
this time period, the insulin resistance of the individual
is continually increasing. This will cause even more AA
formation, especially if consumption of omega-6 fatty acids
remains high. Since the fat cells are now compromised in
their ability to sequester this increased AA production, the
AA levels remain in the blood to be picked up by other
organs.
The ﬁnal development of type 2 diabetes only occurs
when the lipotoxicity has metastasized to the pancreas,
causing a decreased output of insulin [79]. With insulin
secretion decreased, there is a rapid rise of blood sugar
levels. The development of type 2 diabetes indicates that the
metastasis of silent inﬂammation from the adipose tissue to
the pancreas is now complete.
Ironically, even extreme lipotoxicity can be reversed
by the creation of new healthy fat cells. This has been
demonstrated in transgenic obese, diabetic mice that over-
express adiponectin, an adipocyte-derived hormone that
reduces insulin resistance [75]. It is hypothesized that this
increased production of adiponectin activates PPARγ,w h i c h
causes the proliferation of adipose stem cells to produce new
healthy adipocytes. These transgenetic obese mice become
even more obese, but there is a normalization of blood
glucose and lipid levels [75]. This is similar to the elevated
levels of adiponectin found in metabolically healthy obese
individuals [74]. One mechanism of protection against
lipotoxicity might be that the new healthy fat cells in the
adipose tissue can now sequester circulating fatty acids
(including AA) more eﬀectively to allow the resolution of
the inﬂammatory lipid droplets in the muscle, liver and
beta cells of the panaceas. Essentially this resolution process
represents a reverse ﬂow of the lipotoxic lipid droplets in
other organs back to the adipose tissue and reverses insulin
resistance in the muscle and liver cells as well as decreasing
the inﬂammation in the beta cells of the pancreas.
Support of this hypothesis regarding the impact of
AA on fat cell metabolism comes from studies on AA
levels in fat cells on various chronic disease conditions. In
particular, increased AA levels in the fat cells are signiﬁcantly
associatedwithincreasedbodyfat,developmentofmetabolic
syndrome, and incidence of nonfatal heart attacks [44, 50,
80].
11.Anti-InﬂammatoryNutrition
The goal of anti-inﬂammatory nutrition is to understand
how pharmacological targets of inﬂammation can also be
impacted by dietary nutrients. This would include reduction
of those dietary components (a) that directly activate the
inﬂammatory responses of innate immune system that
directly aﬀecting gene transcription factors such as NF-
κB or (b) that indirectly activate NF-κB by interacting
with toll-like receptors or cytokine receptors. These dietary
nutrients that induce an inﬂammatory response can disrupt
hormonal signaling patterns between hormone receptors
and their internal targets giving rise to insulin and leptin
resistance. These dietary nutrients (AA and saturated fats)
that induce inﬂammatory responses via NF-κBa r eo n e s
that must be signiﬁcantly reduced in the diet. Other dietary
components (such as omega-3 fatty acids and polyphe-
nols) that either inhibit toll-like receptors or activate anti-
inﬂammatory gene transcription factors such as PPARα
and PPARγ must be increased to therapeutic levels in
the diet. The combination of these two dietary strategies
should lead to a comprehensive inﬂammatory gene silencing
technology.
Before discussing these molecular targets in detail in the
contextofanti-inﬂammatorynutrition,itisbesttostartwith
our knowledge of the molecular targets in terms of current
anti-inﬂammatory pharmacological approaches used today
especially in the treatment of obesity and diabetes.
12. Pharmacological Targets for
Reducing Inﬂammation
12.1. Anti-Inﬂammatory Drug Targets. If the hypothesis is
correct that obesity is caused by silent inﬂammation, then
modulating molecular targets of anti-inﬂammatory drugs
would hold promise. Anti-inﬂammatory drugs remain the
foundation of medical treatment of pain caused by acute
inﬂammation. The relief of acute pain requires immediate
action with drugs. The more acute the pain, the more
powerful the anti-inﬂammatory drug that has to be used.
Unfortunately, the more powerful the anti-inﬂammatory
drug, the greater the side eﬀects. Our working hypothesis is
that the obesity and the metabolic consequences of obesity
are caused by chronic low-level inﬂammation or silent
inﬂammation. Nonetheless the molecular targets of anti-
inﬂammatory drugs are the same for anti-inﬂammatory
nutrition.6 Journal of Obesity
The classical pathways of anti-inﬂammatory drugs have
been focused on the COX and LOX pathways of eicosanoid
production. Inhibitors of the COX enzymes, such as aspirin
and nonsteroidal anti-inﬂammatory drugs (NSAIDs), have
diﬀerent targets. Aspirin is a suicide inhibitor of the
PGH2 synthase enzyme that is the rate-limiting step of
the formation of pro-inﬂammatory eicosanoids. NSAIDs,
on the other hand, are competitive inhibitors of various
enzymes involved in the generation of pro-inﬂammatory
prostaglandins. However, neither of these drugs has much
eﬀect on the LOX pathways that generates leukotrienes.
Corticosteroids inhibit both the COX and LOX pathways by
inhibiting the release of AA from the phospholipids in the
cell’s membranes.
12.2. Gene Transcription Factor Targets. The key component
of the inﬂammatory response is the activation of NF-κB,
which acts as master genetic switch to cause the express
of inﬂammatory proteins (such as the COX-2 enzyme and
various inﬂammatory cytokines) that ampliﬁes the inﬂam-
matory response. Recent evidence has indicated that aspirin,
salicylates, and statins also inhibit the activation of NF-κB
at high concentrations [11, 12]. It is now hypothesized that
many of the cardiovascular beneﬁts of statins may come
from their anti-inﬂammatory actions as opposed to their
cholesterol-lowering eﬀects [81].
If NF-κB can be considered to be an inﬂammatory gene
transcription factor, then the PPAR family of gene tran-
scription factors can be considered to be anti-inﬂammatory.
There are a number of drugs that activate the PPAR systems.
PPARα is the transcription factor that induces the increased
expression of fat oxidation enzymes. It is this transcription
factor that is activated by drugs such as ﬁbrates [82]. These
drugs are eﬀective in lowering triglyceride levels and are
widely used in cardiovascular treatment. Once the PPARγ
system is activated, it has profound anti-inﬂammatory
eﬀects including the generation of new healthy fat cells
that reduce lipotoxicity. The thiazolidinediones, a mainstay
of diabetes treatment, are examples of such drugs that
activate the PPARγ gene transcription factor [83]. However
unlike omega-3 fatty acids, thiazolidinediones do not have
ap r o t e c t i v ee ﬀect against heart attack [84]. In fact, one of
the more commercially successful thiazolidinediones (i.e.,
rosiglitazone) has been implicated in increased cardiovascu-
lar events [85].
12.3. Regulatory Enzyme Targets. Certain enzymes act as
energy sensors and can regulate a great number of metabolic
systemsespeciallydealingwithglucoseandlipidmetabolism,
especially AMP kinase. The diabetic drug metformin is one
such drug that activates this particular enzyme [86, 87].
This enzyme not only generates adequate levels of ATP, but
also regulates a wide number of enzyme systems involved in
glucose and lipid metabolism [88]. As a result, metformin is
sometimes used as an oﬀ-label weight loss drug [89].
12.4. Hormone Targets. Obviously, the most important hor-
mones in this category are the eicosanoids derived from
AA described earlier. Another group of hormones derived
from AA include endocannabinoids that are involved in gen-
erating hunger. The endocannabinoid receptor antagonist
(rimonabant) was developed as an appetite-suppressant for
the treatment of obesity [90]. This drug was never approved
in the United States due to its various neurological problems,
including an increase in suicidal tendencies. These problems
far overshadowed any potential weight loss beneﬁts.
Other hormones involved in the appetite control come
from the gut, including the satiety hormones PYY and GLP-
1. Currently the only long-term medical intervention to
treat obesity is gastric bypass surgery. The most successful
of these types of surgery is Roux-en-Y gastric bypass that
reroutes much of the small intestine thus delivering most
of the dietary nutrients to the distal part of the small
intestine (i.e., ileum). Unlike other gastric bypass methods,
this surgery also increases the release of gut hormones
such as PYY and GLP-1 from the L-cells in the ileum, to
give a profound degree of satiety [91]. This has led many
drug companies to test various drugs to increase satiety
hormones in order to achieve the same weight loss beneﬁts
of Rous-en-Y bypass surgery. Two diabetic drugs, exenatide
(a GLP-1 receptor agonist) and sitagliptin (an inhibitor of
the enzyme that degrades GLP-1) have demonstrated the
potential for inducing weight loss. Combination products
consisting of hormones such as pramlinitide and leptin
are in various stages of testing, but have not yet been
approved.
12.5. Neurotransmitter Targets. Although we have many
successful examples of drugs for the treatment of acute
inﬂammation, cardiovascular, and diabetes, there are rela-
tively few examples of drugs that are very successful in the
treatment of obesity. The most successful of these drugs
are amphetamines that stimulate dopamine receptors in the
brain leading to increased satiety. Unfortunately, they can
alsoleadtoaddiction[92].Itwasthoughacombinationdrug
knownasfen-phenthatmightcircumventthisproblem.Fen-
phen was a combination of a weaker amphetamine (phenter-
mine) and a powerful serotonin agonist (fenﬂuramine). This
drugcombinationwasdroppedthen,itwasdiscoveredthatit
increased the incidence of primary pulmonary hypertension
and heart valve degeneration [93]. A new combination of
phentermine and the antiepilepsy drug topiramate is under
investigation, but has not yet been approved.
Phentermine and other ampthetamine derivatives are
still in use today for the treatment of obesity but only for
short-term use (approximately 12 weeks). In an eﬀort to
bypass these restrictions, various amphetamine-like drugs
used to treat attention-deﬁcient conditions are often used as
oﬀ-label weight loss drugs.
The only currently approved drugs for long-term treat-
ment of obesity are sibutramine (i.e., structurally similar to
amphetamines) that acts as serotonin and norepinephrine
reuptakeinhibitorandorlistatthatinhibitsthebreakdownof
fat in the GI tract. Unfortunately, neither of these drugs has
demonstrated any signiﬁcant impact in reversing the obesity
epidemic.Journal of Obesity 7
13. Molecular Targets for
anAnti-InﬂammatoryNutrition
With the above as a short review of the pharmacological
targets for reducing inﬂammation or treating obesity, we can
now turn to understanding how various dietary components
can be used to interact with the same molecular targets as
pharmacological agents.
13.1. Pro-Inﬂammatory Nutrients. Anti-inﬂammatory drugs
work by inhibiting the formation of downstream pro-
inﬂammatory eicosanoids derived from AA. A more elegant
approach is to go upstream and reduce the levels of AA
in the cells thereby reducing the substrate required for the
production of pro-inﬂammatory eicosanoids. There is no
known drug that can reduce AA. Only the diet can [94, 95].
The most obvious solution is the reduction of the direct
dietary intake of AA. Dietary sources richest in AA include
organ meats and egg yolks. Other food sources that are
slightly lower in AA content include all animal protein
sources including ﬁsh. It has also been shown that AA has
a direct eﬀect on the activation of NF-κB[ 96]. This may be
mediated by increased leukotriene production [46, 47].
However, even if individuals were following even a strict
vegetarian diet, they would be able to produce large amounts
of AA if that vegetarian diet is rich in both omega-6 fatty
acids and high glycemic index carbohydrates that stimulate
insulin secretion. As described earlier, the combination of
these two dietary factors will increase the production of AA.
Therefore in addition to reducing the direct intake of AA,
one should also have dietary strategy for the simultaneous
reduction of the dietary intake of omega-6 fatty acids, such
aslinoleicacid,andloweringofthelevelsofinsulingenerated
by the diet. Reduction of linoleic acid can be achieved by
using fat sources low in omega-6 fatty acids, such as olive
oil or nuts as well as reducing the consumption of red
meat. Reducing insulin requires a reduction of the glycemic
load of the diet by increasing the consumption of vegetables
and fruits as the primary sources of carbohydrates and
the simultaneous reduction of the consumption of high-
glycemic carbohydrates, such as grains and starches. Another
inﬂammatory nutrient is saturated fatty acids. Saturated fats
can bind to TLR-4 and thus indirectly activate NF-κB[ 97–
102].
Finally, what is often not appreciated is that the total
calorie content of a meal can also raise insulin levels and
increase inﬂammation. Therefore maintaining a calorie-
restricted diet is also essential for insulin control. It has been
demonstrated that overnutrition causes inﬂammation in the
hypothalamus and disrupts the precise signaling balance of
satiety and hunger hormones and thus increases appetite
[103].
13.2. Anti-Inﬂammatory Nutrients. The omega-3 fatty acid
eicosapentaenoic acid (EPA) will have little direct impact
on the reduction of AA because it is a weak inhibitor of
the delta 5-desaturase enzyme; however, at high dietary
intakes, the EPA can dilute out the concentration of AA
in the cell membrane thereby decreasing its potential of
being converted into a pro-inﬂammatory eicosanoids, such
as leukotrienes. As stated earlier, high intakes of EPA can
also reduce inﬂammation in the adipose tissue [70–72].
Thus by either directly inhibiting the formation of AA or
diluting it out by the presence of high levels of EPA in target
cells (especially in the adipose tissue), overall inﬂammation
will be automatically reduced as long there is constant
supplementation with ﬁsh oils rich in EPA.
13.3. Gene Transcription Factors. Inhibition of the NF-κB
is another key anti-inﬂammatory nutrient target. AA can
directly activate NF-κB[ 96] or serve as substrate for the
production of leukotrienes that also appear to activate NF-
κB[ 46, 47]. Thus, the overall reduction of AA will not only
reduce the production of pro-inﬂammatory eicosanoids, but
alsoinhibitthereleaseofgeneproducts(COX-2enzymesand
inﬂammatory cytokines such as TNFα, IL-1, and IL-6) that
are expressed if NF-κBi sa c t i v a t e d .
Omega-3 fatty acids and polyphenols can also inhibit
the activation of NF-κB[ 104, 105]. However, one requires
a therapeutic level of these nutrients to have any signiﬁcant
inhibition of NF-κB. Omega-3 fatty acids can also inhibit the
binding of saturated fats to the TLR-4 on the cell surface thus
also indirectly inhibiting NF-κBa c t i v a t i o n[ 106].
PPARα is the gene transcription factor activated by
ﬁbrates thus increasing the expression of fat oxidation
enzymes needed to lower triglyceride levels. The same
transcription factor can be activated by omega-3 fatty acids,
such as EPA and docosahexaenoic acid (DHA). Both omega-
3fattyacidsappeartoprovideasimilaractivationofthisgene
transcription factor [107]. By reducing the circulating levels
of triglycerides, one also reduces the potential development
of lipotoxicity. In essence, one is using fat (if it is rich in EPA
and DHA) to burn fat by activating PPARα.
PPARγ isanti-inﬂammatorygenetranscriptionfactor.Its
activation creates the stimulus for the production of new
healthy fat cells that enhance the capacity of the adipose
tissueforresequesteringaccumulatedfatinothertissuesthus
reversinglipotoxicity.Thiswillreversemuchofthemetabolic
damage caused by the lipotoxicity, but it may possibily make
the individual fatter in the process. PPARγ is stimulated by
adiponectin whose release from fat cells can be enhanced by
the increased consumption of omega-3 fatty acids [76–78].
In addition, EPA and DHA can also directly activate PPARγ
[108].
13.4. Hormones. Many of the hormones involved in the
control of hunger and satiety are generated by diet. Insulin
is a key hormone in the development of obesity. If insulin
levels remain elevated, the stored fat in the adipose tissue
will remain sequestered due to its inhibition of the hormone
sensitive lipase in healthy fat cells. In addition, insulin in
the blood is a hunger hormone because of its ability to
lower blood glucose levels. Although a diet rich in high-
glycemic carbohydrates will increase the post-prandial levels
of insulin, hyperinsulinemia caused by silent inﬂammation
in the muscle cells will keep insulin constantly elevated.8 Journal of Obesity
This sets up a cycle of increased calorie (primarily carbo-
hydrate) consumption generating increased inﬂammation in
the hypothalamus that dissociates hunger and satiety signals
[103].
Ironically, insulin can also function as a satiety hormone
if it can reach the hypothalamus [109–111]. But if one has
insulin resistance (induced by silent inﬂammation), then the
high levels of insulin in the blood are unable to relay their
message to the key cells in the hypothalamus and potential
satiety eﬀects of insulin are blunted. Leptin is a hormone
released from the fat cells that is also involved in satiety.
Like insulin, it must also reach the hypothalamus to exert its
satiety actions. Obese individuals are characterized by both
insulin and leptin resistance [110–113].
Inhibition of endocannabinoid binding to its receptors
in the brain is the mechanism action of rimonabant. Since
endocannabinoids are derived from AA, reduction of its
levels in the brain should reduce hunger. Unfortunately, the
half-lifeofAAinthebrainislonginhumans[114].However,
increasing the levels of EPA in the brain can inhibit the
bindingofendocannabinoids[115].Sincethehalf-lifeofEPA
in the brain appears to be very short [116], this requires
maintaining a therapeutic level of EPA in the blood to create
aconstantgradientnecessaryfortheconstantﬂowoftheEPA
intothebrain.Thisgradientcanonlybemaintainedbyadiet
either very high in fatty ﬁsh consumption or supplemented
by ﬁsh oil rich in EPA.
As mentioned earlier, much of the success of gastric
bypass surgery is related to the increase in satiety hormones
(PYY and GLP-1) released from the ileum. The release of
these hormones can be enhanced by slowing down the rate
of digestion and absorption of protein and carbohydrate
in a meal so that greater amounts of these nutrients can
reach the L-cells in the ileum. Lowering the glycemic load of
the diet by the inclusion of ﬁber-rich carbohydrate sources
(especially those rich in soluble ﬁber) can slow the digestion
and absorption process of both protein and carbohydrate.
At the same time, increasing the protein content of that
meal will also increase PYY levels [117]. The slower rates
of digestion and absorption mean more of these hormone
agonists will appear in the ileum and thus generate higher
levels of these satiety hormones.
13.5. Neurotransmitters. Amphetamines increase dopamine
levels and decrease hunger [92]. EPA and DHA can also
increase dopamine levels in animal models [118]. It has
been demonstrated that dietary supplementation of high-
dose EPA and DHA can further reduce the symptoms of
attention-deﬁcit hyperactivity disorder (ADHD) in children
already on their optimal level of drugs used to treat this
condition [119, 120].
13.6. AMP Kinase. This particular enzyme is stimulated
by metformin [86, 87]. High levels of polyphenols can
also stimulate the same enzyme [121–123]. Its activation
is a key for not only increasing ATP levels, but also to
regulate lipid and carbohydrate metabolism. As with EPA,
therapeutic levels of polyphenols are required due to their
low bioavailability probably due to their rapid degradation
in the small intestine.
13.7. Increased Thermogenesis. The higher the protein con-
tent of the diet is, the more thermogenesis is increased
[124, 125]. The underlying cause may be activation of
protein synthesis. To activate such protein synthesis requires
a combination of adequate levels of leucine and a consistent
level of insulin in the blood to activate mTOR to stimulate
protein synthesis during the post-prandial period [126].
Data suggest that it takes 20–30 grams of protein at a meal
to stimulate this protein synthesis [127].
14.Developing anAnti-InﬂammatoryDiet
Basedon Anti-InﬂammatoryNutrition
Anti-inﬂammatory nutrition is the understanding how indi-
vidual nutrients aﬀect the same molecular targets aﬀected
by pharmacological drugs. This is only the ﬁrst step in
developing an anti-inﬂammatory diet. Such a diet should
contain all nutrient considerations described above, as well
as being a diet that can promote compliance for a lifetime.
The ﬁrst question would concern the protein, carbohy-
drate, and fat composition for such an anti-inﬂammatory
diet. Currently the dietary recommendations for suggested
fat content in diet range from 20 to 35% of total calories
[128]. Lower-fat diets are simply too diﬃcult to maintain for
a sustained basis as demonstrated in long-term studies [129–
131]. Therefore long-term dietary compliance appears to be
more likely at 30% of total calories as dietary fat. However,
the fat composition must also be low in both omega-6
and saturated fats because of their ability to increase silent
inﬂammation by their interaction with various components
of the innate immune system. The only common dietary fats
that are low in both omega-6 and saturated fats are olive oil
and nuts. Thus they should constitute the bulk of the dietary
fat in any anti-inﬂammatory diet.
The next question is the amount of protein. Most
dieticians would recommend consumption of no more low-
fat protein than would ﬁt on the palm of your hand. This
translates into about 3oz. of a low-fat protein source (this
would contain about 20 grams of amino acids) for a typical
femaleandapproximately4oz.oflow-fatprotein(thiswould
about 30grams of amino acids) for a typical male. These
traditionaldietaryrecommendationsaresupportedbyrecent
research that indicates that this level of high-quality protein
will contain enough of the branched-chain amino acid
leucine to initiate protein synthesis [132]. Furthermore the
absolute intake of protein should be between 20–30grams
at every meal to activate protein synthesis to increase
thermogenesis [124, 127, 132]. If one takes into account
the protein content of carbohydrate sources and potential
snacks, then the average female should be consuming about
80–90grams of low-fat protein per day and the average
male about 100–110grams of low-fat protein per day. This
amount of protein would have to be equally spaced at
each meal to provide the necessary levels of protein forJournal of Obesity 9
the enhanced release of PYY from the L-cells in the ileum
after each meal thereby controlling satiety.
The carbohydrate content should be able to maintain a
stable level of insulin between meals. This can be achieved
with about 40 grams of low glycemic load carbohydrates
at each meal. The vast bulk of the carbohydrates should
come from sources with the highest content of polyphe-
nols with the least amount of carbohydrates, meaning the
consumption of primarily colorful nonstarchy vegetables,
moderate amounts of fruits, limited amounts of whole-
grains, and a radical reduction of the dietary intake of
reﬁned carbohydrates. Although there is some controversy
to whether a low glycemic load diet leads to improved weight
loss [133, 134], there is no question that a low glycemic
load diet will generate a lower inﬂammatory burden [135–
137].
Finally, there is the question of meal timing. The
hormonal control beneﬁts of any meal will last only about
ﬁve hours. To achieve this hormonal control would require
three low-calorie meals and two even lower-calorie snacks
spaced throughout the day so that ﬁve hours never pass
before consuming another meal or snack.
Such a proposed anti-inﬂammatory diet would con-
sist of about 1,500 calories per day (about 50grams of
monounsaturated fat, 100grams of low-fat protein, and
150grams of low glycemic load carbohydrates per day).
This would represent a 1:2:3 ratio of fat to protein to
carbohydrate on a weight basis. On a calorie basis, that is
about 30% of the calories as fat, 30% as protein, and 40%
as carbohydrates. These are the dietary recommendations
made by one of the authors in 1995 [94]. Similar dietary
recommendationsweremadebytheJoslinDiabetesResearch
Center at Harvard Medical School for the treatment of
obesity, metabolic syndrome, and diabetes in 2005 [138]
and conﬁrmed by their own pilot studies [139]. It should
be noted that we believe total calorie consumption should
be driven by protein requirements necessary to maintain a
positive nitrogen balance of essential amino acids, such as
leucine. As an example, a typical female might require a total
of 90grams of protein per day to maintain adequate leucine
levels to stimulate protein synthesis, whereas a male might
require 110grams of total protein per day. Thus using the
macronutrient balance described above, the typical female
would require slightly more than 1300calories per day,
whereas the typical male would require about 1600calories
per day to generate enough chemical energy for daily
metabolic needs. Obviously, higher levels of physical activity
in either the female or male would require higher protein
intake to compensate for the breakdown of muscle protein
during exercise with a corresponding increase in total calorie
consumption [140].
To this anti-inﬂammatory diet foundation should be
added supplemental omega-3 fatty acids at the level of 2-
3grams of EPA and DHA per day either by an increased
consumption of fatty ﬁsh or supplementation with ﬁsh oil
supplements rich in EPA. Finally, a diet rich in colorful, non-
starchy vegetables also would contribute adequate amounts
of polyphenols to help not only to inhibit NF-κB, but also
activate AMP kinase.
In many respects, this proposed anti-inﬂammatory diet
has similarities to a Mediterranean diet. Both are rich in
vegetables and fruits. Both emphasize the moderate intake of
low-fat protein sources, such as chicken and ﬁsh. Both rec-
ommend the use of monounsaturated fats, like olive oil and
nuts. The diﬀerences are in the carbohydrate composition.
An anti-inﬂammatory diet radically restricts the use of bread
and grains (especially reﬁned grain products) and makes up
for it with increased consumption of more colorful (i.e., rich
in polyphenols) vegetables and fruits. That one seemingly
small diﬀerence will have tremendous hormonal and genetic
consequences leading to a lowered inﬂammatory burden.
The goal of an anti-inﬂammatory diet is not weight loss
per se, but the reduction of silent inﬂammation. Of course,
this same reduction of silent inﬂammation should also result
in consistent fat loss if our working hypothesis is correct that
silent inﬂammation is a driving force for the accumulation
of body fat. This is accomplished by aﬀecting the same
molecular targets that have been elucidated by pharmaco-
logical agents. The success of this anti-inﬂammatory diet
can be measured clinically by various markers of silent
inﬂammation as mentioned earlier as well as improvement
of metabolic conditions (i.e., metabolic syndrome, diabetes,
cardiovascular disease, etc.) that are associated with obesity.
15. WhyNotSimplyEatLessandExerciseMore?
Obesity is far more complex than simply it is caused by
calories in being greater than calories out. This is why just
telling obese individuals to eat less and exercise will rarely
work. Obesity is a metabolic condition in which aﬀects
those who are genetically predisposed. Any increase in silent
inﬂammation will cause disruption in metabolic use of fat
coming from the adipose tissue to make adequate levels of
ATP and also cause a dissociation of hunger and satiety
signals in the brain. The combination will leave the obese
individual constantly hungry and thus seeking food. Our
working hypothesis is that the increased levels of silent
inﬂammation generated by the diet cause a disruption in
the signaling mechanisms in both the adipose tissue and the
hypothalamus that leads to the accumulation of excess body
fat.Unlessthoseinﬂammatorydrivingforcesareconsistently
reduced by the diet, the success rate for obese individuals
trying to “eat less and exercise more” will remain abysmal.
This is perhaps best demonstrated by the data derived
from the National Weight Control Registry on individuals
who have lost considerable amounts of weight and have
kept it oﬀ for more than ﬁve years [141, 142]. The average
calorie intake for these individuals is approximately than
1,400caloriesperday,whichisinagreementwithourgeneral
caloric recommendations. Although the National Weight
Control Registry represents a biased reporting population, it
is indicative that our suggested calorie intake is in line with
long-term weight maintenance as long as our recommended
protein amounts are being consumed on a consistent basis
throughout the day. It should also be noted that these
individuals also exercise for approximately one hour per day
whichwould increase theirprotein andcalorie requirements.10 Journal of Obesity
This suggests that our calorie recommendations for seden-
tary individuals may actually be generous.
Implementation of an anti-inﬂammatory diet would
reduce the silent inﬂammation that will make it easier to
not only maintain a reduced weight with less eﬀort, but also




The ultimate treatment of obesity lies in re-establishing
hormonal and genetic balance that generates satiety instead
of constant hunger. This can be achieved by reducing
silent inﬂammation induced by the diet. Pharmacological
agents can pinpoint what those molecular targets are that
induce inﬂammation. The purpose of anti-inﬂammatory
nutrition is to determine which food ingredients can aﬀect
the same molecular targets as drugs and determine what the
therapeutic concentrations are for those nutrients required
to aﬀect the same molecular targets. Only then can you
develop an anti-inﬂammatory diet that has to be used like
a drug at the right time and right level to keep silent
inﬂammation under control.
Obesity is not a consequence of a drug deﬁciency or a
lackof will power, but a lackof knowledge of which nutrients
are necessary and which concentrations that are required to
control silent inﬂammation and therefore control appetite.
Silent inﬂammation is generated by the mismatch of our
current diet and our genes. Anti-inﬂammatory nutrition
should be considered as a form of gene silencing technology,
in particular the silencing of the genes involved in the
generation of silent inﬂammation. Pharmacological agents
often work downstream from the true primary molecular
target of inﬂammation (NF-κB), whereas anti-inﬂammation
nutrition works upstream to reduce the dietary factors
that activate NF-κB to generate silent inﬂammation. Not
only is upstream targeting a more elegant way to treat
obesity with an almost inﬁnite therapeutic index compared
to pharmacological agents, but it also provides a new
approach to treat chronic diseases ultimately caused by silent
inﬂammation.
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